N/A N=6 Treatment

TMS for Post Stroke Depression

Post-stroke Depression

Bottom Line

View on ClinicalTrials.gov: NCT04093843 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2022

Primary outcome: Primary: Number of Participants With Adverse Events — 0 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: TMS (Device)
Age: Adult, Older Adult · 22+ yrs
Sex: All
Sponsor: Amelia Adcock
Primary completion: Jun 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Number of Participants With Adverse Events	—	—
PRIMARY Depressive Symptoms as Rated by the Hamilton Depression Rating Scale	4.667	—
PRIMARY Depressive Symptoms as Rated by the Hamilton Depression Rating Scale	4.667	—
PRIMARY Depressive Symptoms as Rated by the Hamilton Depression Rating Scale	4.667	—
PRIMARY Depressive Symptoms as Rated by the Hamilton Depression Rating Scale	4.667	—
PRIMARY Depressive Symptoms as Rated by the Hamilton Depression Rating Scale	4.667	—

Summary

The purpose of this study is to find alternative treatments for patient's suffering from depression after having a stroke.This study aims to show that accelerated rTMS is a safe, effective,and convenient treatment for patient's suffering from post-stroke depression in the acute to subacute phase. This will be an open label trial and thus all participants will receive the active rTMS intervention.

Eligibility Criteria

Inclusion Criteria

Between the ages of 22-85 years old
Radiographic evidence of acute or subacute stroke
Ischemic stroke diagnosed within the last 2 weeks to 6 months
HAMD depression score 8 or greater
Able to provide written informed consent
Agree to participate in all study procedures

Exclusion Criteria

Metallic objects or neurostimulators implanted intracranially
Stroke in the area of stimulation
Current thoughts of SI or self-harm as assessed by the M.I.N.I. Suicide Scale score > 8
ASRM (Altman Self Rating Mania Scale) score > 6 (6 or above indicates likelihood of manic symptoms)
Current use of illicit substances
Known history of epilepsy or seizure disorder
Clinically significant EKG abnormalities including QTC prolongation >450 ms in men or >480 ms in women

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04093843). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.